Date: {{$ActivityAssignDate}}

Dear Dr. {{$doctorName}},

Subject:Drug utilization pattern of Oral Antidiabetic agents in Management of Patients with Type 2 diabetes Mellitus with CKD with the background of availability of novel classes of Antidiabetic agents (AMPLIFY- II Study)

ICMR INDIAB study estimated that in India 101 million people had diabetes, and the number with prediabetes was 136 million. Diabetes is the most common cause of kidney failure requiring kidney transplantation or dialysis worldwide. The prevalence of CKD among people with diabetes is >25%, and it has been estimated that 40% of people with diabetes develop CKD during their lifetime. The KDIGO guidelines for the management of patients with diabetes and CKD rank SGLT 2 as first line drug for CKD in diabetes. The latest KDIGO guidelines now recommend the use of SGLT2 inhibitors in all patients with diabetes and CKD with eGFR≥20 ml/min and continue if tolerated until dialysis or transplantation. SGLT2 inhibitors are now considered a comprehensive care and not just a glucose lowering therapy.

We at Sun pharmaceutical have planned retrospective, cross-sectional multicenter study to evaluate oral anti-diabetic drug utilization pattern in Indian patients of Type 2 diabetes mellitus (T2DM) with chronic kidney disease in India.

We invite you to participate in this study. On acceptance, you will need to capture the relevant data as mentioned in the standard Data Collection Form (DCF) provided, from the patient’s medical records (case papers and investigational reports – hereafter referred as source documents).

We would recommend you to capture data as outlined in the protocol and whose relevant laboratory investigations are available for the preceding 3 months.

We wish to inform you that the DCF will capture all data in de-identified form and any identifiable parameters that may potentially disclose the identity of the patient such as name or address will be kept strictly confidential. We would encourage you to carefully fill all available information to the fullest as recommended in the DCF.

If you agree to participate in the said study, we would request you to sign and return the enclosed reply along with your visiting card for accuracy of records.